Alliancebernstein L.P. Buys New Position in RA PHARMCTL INC (RARX)

Alliancebernstein L.P. bought a new stake in shares of RA PHARMCTL INC (NASDAQ:RARX) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 10,400 shares of the company’s stock, valued at approximately $195,000.

Several other large investors also recently modified their holdings of the business. JPMorgan Chase & Co. boosted its stake in shares of RA PHARMCTL INC by 33.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 199,900 shares of the company’s stock valued at $3,746,000 after buying an additional 50,432 shares during the period. Candriam Luxembourg S.C.A. acquired a new stake in shares of RA PHARMCTL INC during the 2nd quarter valued at $1,518,000. Geode Capital Management LLC boosted its stake in shares of RA PHARMCTL INC by 8.5% during the 1st quarter. Geode Capital Management LLC now owns 70,863 shares of the company’s stock valued at $1,508,000 after buying an additional 5,522 shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of RA PHARMCTL INC during the 1st quarter valued at $1,455,000. Finally, Spark Investment Management LLC boosted its stake in shares of RA PHARMCTL INC by 74.5% during the 2nd quarter. Spark Investment Management LLC now owns 57,400 shares of the company’s stock valued at $1,075,000 after buying an additional 24,500 shares during the period. 66.74% of the stock is owned by institutional investors.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of RA PHARMCTL INC from a “sell” rating to a “hold” rating in a research note on Tuesday, September 19th. Jefferies Group LLC set a $25.00 target price on shares of RA PHARMCTL INC and gave the company a “buy” rating in a research note on Friday, August 25th. Royal Bank Of Canada assumed coverage on shares of RA PHARMCTL INC in a research note on Thursday, September 14th. They set an “outperform” rating and a $21.00 target price for the company. Finally, Credit Suisse Group lifted their target price on shares of RA PHARMCTL INC from $19.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. RA PHARMCTL INC currently has a consensus rating of “Buy” and a consensus price target of $24.67.

Shares of RA PHARMCTL INC (NASDAQ RARX) opened at $14.11 on Tuesday. RA PHARMCTL INC has a 52 week low of $11.20 and a 52 week high of $27.84.

RA PHARMCTL INC (NASDAQ:RARX) last released its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.06). research analysts forecast that RA PHARMCTL INC will post -2.54 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Alliancebernstein L.P. Buys New Position in RA PHARMCTL INC (RARX)” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/11/14/alliancebernstein-l-p-buys-new-position-in-ra-pharmctl-inc-rarx.html.

RA PHARMCTL INC Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Institutional Ownership by Quarter for RA PHARMCTL INC (NASDAQ:RARX)

Receive News & Ratings for RA PHARMCTL INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA PHARMCTL INC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply